Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registry-Reference-Cited by-同舟云学术

Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registry

Published:2015-09-15 Issue:12 Volume:29 Page:2449-2451
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Dinmohamed A G,van Norden Y,Visser O,Posthuma E F M,Huijgens P C,Sonneveld P,van de Loosdrecht A A,Jongen-Lavrencic M

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2015220.pdf

Reference8 articles.

1. Bernal T, Martinez-Camblor P, Sanchez-Garcia J, de Paz R, Luno E, Nomdedeu B et al. Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: Results from the Spanish Registry. Leukemia 2015; 29: 1875–1881.

2. Schouten LJ, Hoppener P, van den Brandt PA, Knottnerus JA, Jager JJ . Completeness of cancer registration in Limburg, The Netherlands. Int J Epidemiol 1993; 22: 369–376.

3. Dinmohamed AG, Visser O, van Norden Y, Huijgens PC, Sonneveld P, van de Loosdrecht AA et al. Trends in incidence, initial treatment and survival of myelodysplastic syndromes: a population-based study of 5144 patients diagnosed in the Netherlands from 2001 to 2010. Eur J Cancer 2014; 50: 1004–1012.

4. Dinmohamed AG, van Norden Y, Visser O, Posthuma EF, Huijgens PC, Sonneveld P et al. The use of medical claims to assess incidence, diagnostic procedures and initial treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia in the Netherlands. Leuk Res 2015; 39: 177–182.

5. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10: 223–232.

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical activity, pharmacokinetics, and pharmacodynamics of oral hypomethylating agents for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: A multidisciplinary review;Journal of Oncology Pharmacy Practice;2024-03-21

2. Real-world data of MDS and CMML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11);International Journal of Hematology;2023-12-13

3. Clinical Outcomes in Patients With Refractory Anemia With Excess Blasts (RAEB) Who Receive Hypomethylating Agents (HMAs);Clinical Lymphoma Myeloma and Leukemia;2023-10

4. Cox proportional hazards deep neural network identifies peripheral blood complete remission to be at least equivalent to morphologic complete remission in predicting outcomes of patients treated with azacitidine—A prospective cohort study by the AGMT;American Journal of Hematology;2023-08-07

5. STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2;Future Oncology;2023-03